Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Single-Arm Study of Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

NCT05896228 is registered in ClinicalTrials.gov with Benjamin T Diamond, MD as lead sponsor.

NCT NCT05896228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05896228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Single-Arm Study of Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Benjamin T Diamond, MD
Phase
Phase 2
Overall status
Recruiting
Start date
February 20, 2024
Completion date
March 1, 2031
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma, relapsed multiple myeloma